Prof. Erika Lietzan

Professor Lietzan Speaks on Panel at Supreme Court IP Review

November 6th, 2017

Professor Erika Lietzan recently served as a panelist at the Supreme Court IP Review held at the Chicago-Kent College of Law. She discussed Sandoz, Inc. v. Amgen. Inc., a case decided by the Supreme Court last June.

Read More

Pan American Journal of Public Health Publishes Letter from Professor Lietzan

October 13th, 2017

The Pan American Journal of Public Health published a letter from Professor Erika Lietzan, in which she responds to an article about Colombia’s pathways for approval of biosimilar biologics. A 2014 presidential decree in Colombia allowed for

Read More

Professor Lietzan Named Best Lawyer in FDA Law and Biotechnology Law

August 23rd, 2017

Professor Lietzan has again been named a “Best Lawyer in America” in both FDA Law and Biotechnology Law. This marks the fifth year in a row for FDA Law and the eleventh year in a row for

Read More

Erika Lietzan Featured on ‘The Week in Health Law’ Podcast

August 18th, 2017

Professor Lietzan was recently a guest on “This Week in Health Law,” a commuting-length podcast that tackles thorny issues in health law and policy. She discussed her research on the relationship between drug innovation and incentives for

Read More

Professor Lietzan Participates in Center for the Protection of Intellectual Property Summer Institute

July 21st, 2017

Professor Erika Lietzan recently attended the 2017 Summer Institute, hosted by the Center for the Protection of Intellectual Property at Antonin Scalia Law School, George Mason University. She presented “The Drug Innovation Paradox,” which will be published

Read More